Oldenburg B - Search Results

1

Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.

Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Schultheiss JPD, et al. Among authors: oldenburg b. Aliment Pharmacol Ther. 2021 Nov;54(10):1298-1308. doi: 10.1111/apt.16605. Epub 2021 Sep 24. Aliment Pharmacol Ther. 2021. PMID: 34559428 Free PMC article.

2

Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications?

Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Oldenburg B, et al. Am J Gastroenterol. 2000 Oct;95(10):2825-30. doi: 10.1111/j.1572-0241.2000.03193.x. Am J Gastroenterol. 2000. PMID: 11051355

3

Iron and inflammatory bowel disease.

Oldenburg B, Koningsberger JC, Van Berge Henegouwen GP, Van Asbeck BS, Marx JJ. Oldenburg B, et al. Aliment Pharmacol Ther. 2001 Apr;15(4):429-38. doi: 10.1046/j.1365-2036.2001.00930.x. Aliment Pharmacol Ther. 2001. PMID: 11284771 Free article. Review.

4

Chemiluminescence in inflammatory bowel disease patients: a parameter of inflammatory activity.

Oldenburg B, van Kats-Renaud H, Koningsberger JC, van Berge Henegouwen GP, van Asbeck BS. Oldenburg B, et al. Clin Chim Acta. 2001 Aug 20;310(2):151-6. doi: 10.1016/s0009-8981(01)00569-1. Clin Chim Acta. 2001. PMID: 11498080

5

Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease.

van Balkom BP, Schoon EJ, Stockbrügger RW, Wolters FL, van Hogezand RA, van Deventer SJ, Oldenburg B, van Dullemen HM, Russel MG. van Balkom BP, et al. Among authors: oldenburg b. Aliment Pharmacol Ther. 2002 Jun;16(6):1101-7. doi: 10.1046/j.1365-2036.2002.01268.x. Aliment Pharmacol Ther. 2002. PMID: 12030951 Free article. Clinical Trial.

6

High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency.

Minderhoud IM, Oldenburg B, van Dam PS, van Berge Henegouwen GP. Minderhoud IM, et al. Among authors: oldenburg b. Am J Gastroenterol. 2003 May;98(5):1088-93. doi: 10.1111/j.1572-0241.2003.07414.x. Am J Gastroenterol. 2003. PMID: 12809832

7

IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior.

Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. Minderhoud IM, et al. Among authors: oldenburg b. Dig Dis Sci. 2004 Mar;49(3):469-74. doi: 10.1023/b:ddas.0000020506.84248.f9. Dig Dis Sci. 2004. PMID: 15139501

8

Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia.

Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP. Oldenburg B, et al. Dig Dis Sci. 2005 Feb;50(2):235-40. doi: 10.1007/s10620-005-1588-y. Dig Dis Sci. 2005. PMID: 15745078

9

Biological therapies in inflammatory bowel disease: top-down or bottom-up?

Oldenburg B, Hommes D. Oldenburg B, et al. Curr Opin Gastroenterol. 2007 Jul;23(4):395-9. doi: 10.1097/MOG.0b013e32815b601b. Curr Opin Gastroenterol. 2007. PMID: 17545775 Review.

10

High frequency of early colorectal cancer in inflammatory bowel disease.

Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Oldenburg B, Samsom M. Lutgens MW, et al. Among authors: oldenburg b. Gut. 2008 Sep;57(9):1246-51. doi: 10.1136/gut.2007.143453. Epub 2008 Mar 12. Gut. 2008. PMID: 18337322

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

553 results

Search Page